Altimmune, Inc. (ALT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Altimmune, Inc. (ALT) closed at USD 2.31 on 2026-10-14, a change of -43.1 % over the past year, with a market capitalization of USD 459.06M.

Altimmune, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Altimmune, Inc. key figures

Previous close

USD 2.31 (2026-10-14)

1-year change

-43.1 %

Market cap

USD 459.06M

Enterprise value

USD 168.8M

P/E ratio (trailing)

-3.19

P/E ratio (forward)

-3.53

EPS (trailing)

-0.74

EPS (forward)

-0.67

PEG ratio

32.62

Price to book

0.97

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.98

Employees

57

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Altimmune, Inc.

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Altimmune, Inc. and compare it with other stocks.